<DOC>
	<DOCNO>NCT01714336</DOCNO>
	<brief_summary>Does tranexamic acid improve perioperative care patient treat surgically hip fracture decrease proportion patient require transfusion decrease total perioperative bleeding .</brief_summary>
	<brief_title>Does Tranexamic Acid Reduce Need Blood Transfusions Patients Undergoing Hip Fracture Surgery ?</brief_title>
	<detailed_description>Antifibrinolytic medication tranexamic acid , aprotinin , aminocaproic acid proven useful decrease blood loss proportion patient require transfusion number surgical procedure . In orthopedic surgery , tranexamic acid ( TXA ) best study medication recent Cochrane Database review determine tranexamic acid effective decrease perioperative bleed post-operative transfusion elective hip replacement knee replacement surgery . At Mayo Clinic Rochester , routine administration tranexamic acid evolve past decade become part typical protocol 3,000 elective hip knee replacement procedure year . Recent administrative data provide fairly compelling evidence efficacy tranexamic acid decrease transfusion Mayo Clinic Rochester practice 2010 data show 2 % 7 % prevalence transfusion patient treat tranexamic acid versus 18 % 33 % prevalence knee hip replacement patient , respectively , treat tranexamic acid . A recent analysis Mayo Clinic Rochester orthopedic practice show patient treated hip fracture remain substantial risk perioperative transfusion ( 30 % prevalence ) operative management . This raise question whether tranexamic acid could improve perioperative care patient treat surgically hip fracture decrease proportion patient require transfusion decrease total perioperative bleeding .</detailed_description>
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Hip Fractures</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Inclusion criterion AO/OTA ( Orthopedic Trauma Association ) fracture classification 31B Surgically treat either hemiarthroplasty total hip arthroplasty Acute fracture treat within 72 hour injury Low energy isolate injury Age great 18 year old Exclusion Criteria Transfusion receive admission , prior surgery Creatinine clearance le 30 mL/min History unprovoked Venous Thromboembolism ( VTE ) and/or recurrent VTE Known history Factor V Leiden , protein C/S deficiency , prothrombin gene mutation , antithrombin deficiency , antiphospholipid antibody syndrome , lupus anticoagulant Pregnancy breastfeeding ( pregnancy test perform patient childbearing potential ) History cerebrovascular accident ( CVA ) , Myocardial infarction ( MI ) , VTE within previous 30 day Coronary stent placement within previous 6 month Disseminated intravascular coagulation Subarachnoid hemorrhage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Arbeitsgemeinschaft f√ºr Osteosynthesefragen ( AO ) fracture</keyword>
	<keyword>Orthopaedic Trauma Association ( OTA ) fracture</keyword>
</DOC>